Tempus AI (TEM) Stock Could Be 33% Undervalued Following Cancer Vaccine News
Tempus AI stock has rallied strongly in the past month, yet its valuation checks are pulling in different directions, with an intrinsic value estimate based on a Discounted Cash Flow (DCF) pointing to upside while market multiples lean expensive.
- Tempus AI has returned 54.8% over the past month, which puts extra focus on whether recent optimism is already reflected in the share price.
- The surge in interest following positive cancer vaccine trial news and the planned US$1.5b Personalis acquisition may support expectations for future oncology diagnostics revenue. At the same time, integration risk and execution on that deal can weigh on how much of that potential ultimately shows up in cash flows.
- On Simply Wall St's broader valuation checks, Tempus AI only passes 2 of 6 tests. This suggests the stock does not screen as a clear bargain on most measures, even though the DCF indicates it is 33.1% below intrinsic value according to the valuation score of 2.
The issue now is whether the recent rally in Tempus AI leaves enough upside relative to its intrinsic value estimate to still appeal to investors focused on price versus fundamentals.
Find out why Tempus AI's -9.7% return over the last year is lagging behind its peers.
Is Tempus AI a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here uses projected free cash flows to estimate what Tempus AI might be worth today. Tempus AI is currently generating negative free cash flow over the last twelve months, with an outflow of about $274.1 million, yet the model assumes these cash flows recover and grow in the coming years. On that basis, the DCF points to an estimated intrinsic value of about $109 per share.
Compared with the recent share price, that intrinsic value implies the stock is 33.1% undervalued. The strong reaction to the Merck and Moderna cancer vaccine trial, which supports Tempus AI's planned Personalis acquisition, helps explain why investors are now willing to pay closer to what the projected cash flows suggest.
Overall, the Discounted Cash Flow valuation suggests Tempus AI stock currently looks undervalued relative to its projected cash generation.
Our Discounted Cash Flow (DCF) analysis suggests Tempus AI is undervalued by 33.1%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks.
Has Tempus AI Run Too Far on Sales?
The price-to-sales (P/S) ratio is often useful for Tempus AI because the company is still focused on revenue growth while reporting losses and negative free cash flow.
Tempus AI currently trades on a P/S of about 9.2x. That is higher than the Life Sciences industry average of around 4.6x and also above the peer group average of about 6.0x. The modelled fair P/S ratio for Tempus AI is about 8.2x, which already factors in its growth profile, margins, size and risk.
Compared with that fair ratio, the current 9.2x multiple suggests investors are paying a premium for Tempus AI's sales. The gap is not extreme, yet it indicates that recent enthusiasm around oncology diagnostics and the Personalis deal leaves the stock screening as expensive on a P/S basis.
On the P/S multiple, Tempus AI stock currently screens as overvalued relative to what its revenue profile would usually justify.
See what the numbers say about this price — find out in our valuation breakdown.
The Tempus AI Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where this Tempus AI valuation puzzle leaves off and sets out which assumptions on growth, margins and future earnings would need to be true for Tempus AI's stock to be worth materially more or less than today’s price on the Community page. Each narrative presents fair value as a clear thesis about the business that you can revisit over time, rather than a one off snapshot.
Community views on Tempus AI are split, with some seeing a data platform opportunity and others focusing on execution and monetisation risk.
Bull case: 24% undervalued
"Industry focus on using data and AI to reduce clinical error and waste, together with Tempus AI's installed base across more than 5,000 hospitals and a large library of FDA cleared algorithms, creates an opportunity for new reimbursed “dry lab” services that could add incremental high margin revenue beyond the wet lab business…"
Read the full Bull Case to see why Tempus AI could be undervalued
Bear case: 10% overvalued
"This data moat is what makes the business interesting…"
Read the full Bear Case to see why Tempus AI could be overvalued
Do you think there's more to the story for Tempus AI? Head over to our Community to see what others are saying!
The Bottom Line
Tempus AI offers a split message on value. The Discounted Cash Flow (DCF) view points to meaningful upside on an intrinsic value basis, while the P/S multiple signals that the stock is already priced at a premium to its current revenue profile. The low broader value score suggests investors should treat the DCF signal with caution rather than as a clear green light. The key question from here is whether Tempus AI can translate its oncology diagnostics opportunity and the planned Personalis acquisition into cash flows that justify both the intrinsic value estimate and the premium sales multiple investors are currently paying.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com